Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-001 in Moderately to Severely Active Ulcerative Colitis
NCT07374471Phase 2Recruiting
- Sponsor
- Mage Biologics Inc.
- Start
- Apr 2026
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of MB-001 in ulcerative colitis (UC), sponsored by Mage Biologics Inc.. Started Apr 2026; status: recruiting.
02
Drugs
MB-001
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07374471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07374471.